Dianthus priced 7,313,582 shares and pre-funded warrants for 402,468 shares at $81.00, for $624,999,648 in total, after launching a $400,000,000 offering. Its 2025 net loss was $162.3 million, and the supplement names no counsel.
Latest Dianthus Therapeutics news
We have not published a story on Dianthus Therapeutics yet. When there is news, it will appear here.
Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $110.5 million, plus short-term investments of $776.3 million, $886.8 million in all.
Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.
Questions about Dianthus Therapeutics
Has Dianthus Therapeutics raised money recently?
Our latest story on this, dated Mar 9, 2026: "Dianthus launches $400,000,000 stock offering, then prices it at $81.00 a share". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of Dianthus Therapeutics?
Dianthus Therapeutics, Inc. trades under the ticker DNTH on NASDAQ.
Where is Dianthus Therapeutics listed?
Dianthus Therapeutics, Inc. is listed on NASDAQ. Our directory also records these other listings: DUS:87E; FWB:87E; GETTEX:87E; LSX:A3ERZ4; MUN:87E; SWB:87E; TRADEGATE:87E; XETR:87E.
What is the SEC CIK of Dianthus Therapeutics?
The SEC Central Index Key (CIK) for Dianthus Therapeutics, Inc. is 1690585. Its filings are on SEC EDGAR.
How many shares does Dianthus Therapeutics have outstanding?
55,934,378 shares as of 2026-08-03, per the cover page of its 10-Q filed 2026-08-04.
Which country or territory is Dianthus Therapeutics listed under?
Our directory records Dianthus Therapeutics, Inc. under United States.
What does Dianthus Therapeutics do?
Our directory classifies Dianthus Therapeutics, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
What is the ISIN of Dianthus Therapeutics?
The ISIN recorded for Dianthus Therapeutics, Inc. is US2528281080.
Does aibio.space cover Dianthus Therapeutics?
aibio.space lists Dianthus Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Dianthus Therapeutics incorporated?
SEC records list its state or country of incorporation as DE.
What was Dianthus Therapeutics's revenue last year?
$2.0 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Is Dianthus Therapeutics profitable?
Dianthus Therapeutics, Inc. reported a net loss of $162.3 million for the fiscal year ended Dec 31, 2025, and used $129.1 million of cash in operations, per its annual report to the SEC.
How much does Dianthus Therapeutics spend on research and development?
$145.6 million in the fiscal year ended Dec 31, 2025, per its annual report.
How much cash does Dianthus Therapeutics have?
$886.8 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.
What is the latest Dianthus Therapeutics (DNTH) stock news?
Our latest story on Dianthus Therapeutics, dated Mar 9, 2026: "Dianthus launches $400,000,000 stock offering, then prices it at $81.00 a share". Dianthus priced 7,313,582 shares and pre-funded warrants for 402,468 shares at $81.00, for $624,999,648 in total, after launching a $400,000,000 offering. Its 2025 net loss was $162.3 million, and the supplement names no counsel. Source.
Investor discussion: Dianthus Therapeutics
Members talk about Dianthus Therapeutics (DNTH). Reader posts, not aibio.space reporting, and not investment advice.
Rules
Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.
Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.
Capital-markets timeline
Financings, listing notices, splits, legal actions and other investor events at Dianthus Therapeutics, newest first. Each line links the filing it comes from.
Financings
Set up an at-the-market program to sell shares over time. SEC Form 424B5. Source
Financings
Set up an at-the-market program to sell shares over time. SEC Form 424B5. Source
Stock chart
Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open NASDAQ:DNTH on TradingView.
SEC filings and registration
SEC name
Dianthus Therapeutics, Inc. /DE/
CIK
1690585
Industry (SIC)
Pharmaceutical Preparations (2834)
US tickers
DNTH (Nasdaq)
State or country of incorporation
DE
Fiscal year ends
December 31
Filer category
Non-accelerated filer<br>Smaller reporting company
Business address
7 TIMES SQUARE, NEW YORK, NY, 10036
Phone
929-999-4055
Shares outstanding
55,934,378 as of 2026-08-03 (10-Q filed 2026-08-04)
Former names
Magenta Therapeutics, Inc.
Recent filings (8-K and 6-K are the company's own announcements)
Source: SEC EDGAR, retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.
Listing details
Dianthus Therapeutics, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker DNTH, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.
Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.
Published and maintained by aibio.space. Not investment advice. How we work.
Who manages this pageThis page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio